NEW YORK (GenomeWeb) – Affymetrix today announced that it has signed a deal to collaborate with MTI subsidiary EverGene on a personal genomics service for the Japanese market.

Under the deal, Affymetrix's Axiom genotyping platform will be used with EverGene's DearGene Starter Kit, a consumer genotyping service that provides information about an individual's risk for disease. Samples for the kit are processed exclusively by Takara Bio, according to a joint statement released by Affy and EverGene.

Financial terms of the supply agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.